Imperial College London
Alternate

ProfessorSimakAli

Faculty of Medicine, Department of Surgery & Cancer

Professor of Molecular Endocrine Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2811simak.ali

 
 
//

Location

 

133ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Brooke:2014:10.18632/oncotarget.1360,
author = {Brooke, GN and Powell, SM and Lavery, DN and Waxman, J and Buluwela, L and Ali, S and Bevan, CL},
doi = {10.18632/oncotarget.1360},
journal = {Oncotarget},
pages = {959--969},
title = {Engineered repressors are potent inhibitors of androgen receptor activity},
url = {http://dx.doi.org/10.18632/oncotarget.1360},
volume = {5},
year = {2014}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Prostate cancer growth is dependent upon the Androgen Receptor (AR) pathway, hence therapies for this disease often target this signalling axis. Such therapies are successful in the majority of patients but invariably fail after a median of 2 years and tumours progress to a castrate resistant stage (CRPC). Much evidence exists to suggest that the AR remains key to CRPC growth and hence remains a valid therapeutic target. Here we describe a novel method to inhibit AR activity, consisting of an interaction motif, that binds to the AR ligand-binding domain, fused to repression domains. These ‘engineered repressors’ are potent inhibitors of AR activity and prostate cancer cell growth and importantly inhibit the AR under circumstances in which conventional therapies would be predicted to fail, such as AR mutation and altered cofactor levels.
AU  - Brooke,GN
AU  - Powell,SM
AU  - Lavery,DN
AU  - Waxman,J
AU  - Buluwela,L
AU  - Ali,S
AU  - Bevan,CL
DO  - 10.18632/oncotarget.1360
EP  - 969
PY  - 2014///
SN  - 1949-2553
SP  - 959
TI  - Engineered repressors are potent inhibitors of androgen receptor activity
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.1360
UR  - http://hdl.handle.net/10044/1/29638
VL  - 5
ER  -
Download